Progyny Inc (NASDAQ:PGNY) major shareholder Group Holdings (Sbs) Advis Tpg sold 16,100 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $26.34, for a total value of $424,074.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Group Holdings (Sbs) Advis Tpg also recently made the following trade(s):

  • On Tuesday, July 21st, Group Holdings (Sbs) Advis Tpg sold 117,620 shares of Progyny stock. The shares were sold at an average price of $26.16, for a total value of $3,076,939.20.
  • On Wednesday, July 8th, Group Holdings (Sbs) Advis Tpg sold 33,412 shares of Progyny stock. The shares were sold at an average price of $25.71, for a total value of $859,022.52.
  • On Thursday, July 2nd, Group Holdings (Sbs) Advis Tpg sold 66,381 shares of Progyny stock. The shares were sold at an average price of $26.27, for a total value of $1,743,828.87.
  • On Monday, July 6th, Group Holdings (Sbs) Advis Tpg sold 110,000 shares of Progyny stock. The shares were sold at an average price of $26.43, for a total value of $2,907,300.00.
  • On Tuesday, June 23rd, Group Holdings (Sbs) Advis Tpg sold 70,000 shares of Progyny stock. The shares were sold at an average price of $24.93, for a total value of $1,745,100.00.
  • On Tuesday, June 9th, Group Holdings (Sbs) Advis Tpg sold 180,000 shares of Progyny stock. The shares were sold at an average price of $24.74, for a total value of $4,453,200.00.
  • On Thursday, May 28th, Group Holdings (Sbs) Advis Tpg sold 9,648 shares of Progyny stock. The stock was sold at an average price of $25.12, for a total value of $242,357.76.
  • On Friday, May 15th, Group Holdings (Sbs) Advis Tpg sold 120,000 shares of Progyny stock. The stock was sold at an average price of $24.69, for a total value of $2,962,800.00.
  • On Tuesday, May 5th, Group Holdings (Sbs) Advis Tpg sold 67,304 shares of Progyny stock. The stock was sold at an average price of $22.70, for a total value of $1,527,800.80.

Shares of PGNY opened at $26.63 on Friday. The stock has a 50 day moving average of $25.34 and a 200-day moving average of $25.30. Progyny Inc has a 52 week low of $13.29 and a 52 week high of $36.50.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, May 12th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. The firm had revenue of $81.02 million during the quarter, compared to analyst estimates of $71.81 million. The company’s revenue for the quarter was up 71.7% on a year-over-year basis. Equities analysts expect that Progyny Inc will post 0.17 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Clearbridge Investments LLC boosted its position in Progyny by 12.5% during the 1st quarter. Clearbridge Investments LLC now owns 1,619,494 shares of the company’s stock valued at $34,317,000 after purchasing an additional 180,432 shares during the period. Nuveen Asset Management LLC boosted its position in Progyny by 392.4% during the 1st quarter. Nuveen Asset Management LLC now owns 146,181 shares of the company’s stock valued at $3,098,000 after purchasing an additional 116,493 shares during the period. State Street Corp boosted its position in Progyny by 36.1% during the 1st quarter. State Street Corp now owns 196,213 shares of the company’s stock valued at $4,158,000 after purchasing an additional 52,011 shares during the period. Alliancebernstein L.P. acquired a new position in Progyny during the 1st quarter valued at approximately $574,000. Finally, Victory Capital Management Inc. boosted its position in Progyny by 242.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,118 shares of the company’s stock valued at $130,000 after purchasing an additional 4,331 shares during the period. Institutional investors and hedge funds own 38.04% of the company’s stock.

Several research firms have issued reports on PGNY. SVB Leerink began coverage on Progyny in a report on Wednesday, July 1st. They set an “outperform” rating and a $35.00 price objective on the stock. Guggenheim began coverage on Progyny in a report on Tuesday, June 2nd. They set a “buy” rating and a $30.00 price objective on the stock. Citigroup dropped their price objective on Progyny from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Zacks Investment Research upgraded Progyny from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Bank of America lifted their price objective on Progyny from $26.00 to $28.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Progyny currently has a consensus rating of “Buy” and a consensus target price of $29.63.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Read More: Why is the LIBOR significant?

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.